Finvest
ONC Biotechnology · Oncology · Global pharma · Blood cancer · Thesis updated July 15, 2026

BRUKINSA leads, but patents matter

01 Running thesis

One leader, one legal overhang

BeOne is no longer a small biotech waiting for a first hit. BRUKINSA, its blood cancer drug, is the global revenue leader in the BTK inhibitor class. A BTK inhibitor blocks a growth signal used by some blood cancer cells. In Q1 2026, BRUKINSA revenue rose 38% to $1.1 billion, while total global revenue rose 35% to $1.5 billion.

The bull case is that BeOne can turn one large drug into a broader cancer franchise. BRUKINSA already captures about half of the continuous-use BTK market, based on management commentary. The ZS plan, zanubrutinib plus sonrotoclax, could let BeOne enter the other half of the CLL market that prefers fixed-time treatment. Sonrotoclax, a BCL2 drug that pushes cancer cells toward death, already has its first China approval for relapsed or hard-to-treat mantle cell lymphoma and CLL or SLL.

The business also looks healthier than it used to. Q1 2026 GAAP diluted earnings per ADS were $1.96, and the company had $4.9 billion of cash, cash equivalents, and restricted cash at quarter end. That supports a high financial health view, even while BeOne keeps spending on sales teams, trials, and new drug ideas.

The bear case is that the lead drug is now big enough to attract serious attacks. Zydus filed a generic drug application for BRUKINSA tablets, and BeOne filed a Hatch-Waxman patent suit in February 2026. AbbVie also alleges trade secret misuse tied to the BGB-16673 BTK degrader program. These disputes may not break the company, but they can change how investors value the pipeline and the life of BRUKINSA.

May 2026▲Q1 2026 total global revenue rose 35% to $1.5 billion, and BRUKINSA revenue rose 38% to $1.1 billion. The thesis stays centered on BRUKINSA scale and the next sonrotoclax catalyst.
Feb 2026▲Management said BRUKINSA became number one in the U.S. and globally in 2025. The ZS fixed-time CLL plan became a clearer growth path.
Feb 2026▼The FY2025 filing added a new generic risk after Zydus filed an ANDA for BRUKINSA tablets. BeOne responded with a patent suit, making IP a bigger watch item.
Nov 2025▲Q3 2025 revenue grew 41% to $1.4 billion, and BRUKINSA grew 51% to $1.0 billion. The company also said BRUKINSA was the global revenue leader in BTK inhibitors.
Nov 2025▲Management raised 2025 revenue guidance to $5.1 billion to $5.3 billion. It also kept the plan to move about 10 new molecular entities into clinical trials by the end of 2025.
Aug 2025▲Q2 2025 revenue reached $1.3 billion, and BRUKINSA revenue was $950 million. The new tablet formulation improved the cost story.
Aug 2025▲BeOne redomiciled to Switzerland and reported GAAP diluted earnings per ADS of $0.84 in Q2 2025. The USPTO update also reduced one BRUKINSA patent overhang.
May 2025▲Management said BRUKINSA had passed rival BTK inhibitors in U.S. quarterly revenue. BeOne also reached GAAP profitability for the first time in Q1 2025.
02 Business model

Own the drug, sell it globally

BeOne discovers, develops, and sells cancer medicines. It uses its own commercial teams in major markets and also uses partners, including Amgen, especially for in-licensed products in China.

Most money comes from product sales. In Q1 2026, product revenue was $1.49 billion out of $1.51 billion in total revenue. BRUKINSA was by far the largest line, followed by TEVIMBRA and Amgen in-licensed products sold in China.

The model improves as BRUKINSA scales. The company said product gross margin rose to 88.8% in Q1 2026, helped by a higher BRUKINSA mix and production gains. The new BRUKINSA tablet formulation also lowers product cost, which can help margins if uptake stays strong.

Where it can break is clear. Cancer drug markets are crowded, and payers can push back on price. China can pressure drug prices more than the U.S. or Europe. The company also relies on clean trial results, regulatory approvals, patent protection, and supply chains that cross regions.

03 Product portfolio

What BeOne sells and bets on

Growth engine

BRUKINSA

BRUKINSA is the core asset and the largest revenue source. It treats blood cancers and led the BTK inhibitor class by global revenue in 2025.

Steady

TEVIMBRA

TEVIMBRA is an immuno-oncology drug sold in China and the U.S. It adds a second commercial pillar, with Q1 2026 sales of $206.2 million.

Option

Sonrotoclax

Sonrotoclax is a BCL2 inhibitor with its first China approval for relapsed or hard-to-treat MCL and CLL or SLL. Its bigger role may be in the ZS fixed-time combo with BRUKINSA.

Option

ZS combination

ZS combines zanubrutinib and sonrotoclax. Management says it could open the fixed-time CLL market where BeOne does not yet have a major presence.

Steady

Amgen in-licensed products

Products such as XGEVA, BLINCYTO, and KYPROLIS add China revenue through the Amgen relationship. Q1 2026 Amgen product revenue in China totaled $142.2 million.

Option

BGB-16673

BGB-16673 is a BTK degrader, a drug meant to remove the BTK protein rather than just block it. It has EMA PRIME designation, but it also sits inside the AbbVie trade secret lawsuit.

Option

Solid tumor programs

BeOne is advancing antibody drug conjugates and multispecific antibodies, including B7H4 ADC and GPC3x41BB. These could matter if they show clear benefit in larger trials.

04 Business segments

BRUKINSA dominates the mix

BRUKINSA72%growing fast
TEVIMBRA14%modest
Amgen in-licensed products9%modest
Other products and other revenue5%growing fast

Revenue mix uses Q1 2026 total revenue from the latest 10-Q. Shares are rounded, and the key caveat is concentration: BRUKINSA alone was about 72% of total revenue.

05 Risk factors

What could go wrong

Generic BRUKINSA tablet challenge

High impact · Medium odds

Zydus filed a generic drug application seeking FDA approval for BRUKINSA tablets. BeOne sued under the Hatch-Waxman Act in February 2026. A bad outcome could shorten the protected cash life of BeOne's largest product.

We watchCourt updates in the Zydus ANDA case and any FDA action tied to the generic BRUKINSA tablet filing.

AbbVie trade secret lawsuit

Medium impact · Medium odds

AbbVie alleges trade secret misuse tied to the BGB-16673 BTK degrader program. BGB-16673 is not the main revenue driver today, but it is an important pipeline option. Litigation could cost money, slow development, or limit the asset.

We watchRulings, settlement terms, injunction requests, or trial timing in the AbbVie case.

CLL combo data misses

High impact · Medium odds

The ZS combo is central to the next growth story because it targets fixed-time CLL treatment. If trial data do not show a clean balance of response, safety, and treatment length, BeOne may stay locked out of a large part of the market.

We watchSonrotoclax and ZS response rates, safety data, trial discontinuations, and FDA or EU review updates.

Geopolitics and supply chain stress

Medium impact · Medium odds

BeOne operates across the U.S., China, Europe, and Switzerland. Tariffs, export controls, or drug import reviews could raise cost or slow supply. Management says 2025 tariff effects were managed through regional supply planning, but a sharper policy shift remains a risk.

We watchNew U.S.-China tariff rules, U.S. BIS pharmaceutical import findings, and management comments on inventory or manufacturing moves.

Pricing and competition

Medium impact · High odds

BRUKINSA competes against other BTK drugs, and TEVIMBRA competes in crowded immuno-oncology markets. China can also force lower prices through reimbursement talks. Even if volumes rise, weaker pricing can cap profit growth.

We watchBRUKINSA new patient share, U.S. net pricing comments, China reimbursement changes, and European market share trends.
06 Quick answers

In one breath

What does BeOne Medicines do?

BeOne Medicines develops and sells cancer drugs. Its biggest product is BRUKINSA, a BTK inhibitor used for blood cancers.

Why is BRUKINSA so important to ONC stock?

BRUKINSA made $1.1 billion in Q1 2026 revenue, which was about 72% of total revenue. That makes the company much stronger, but also more exposed if patents, pricing, or competition go against it.

What is the ZS combination?

ZS is zanubrutinib plus sonrotoclax. The goal is a fixed-time treatment for CLL, which means patients take therapy for a set period instead of staying on continuous treatment.

Is BeOne profitable now?

BeOne reported Q1 2026 GAAP diluted earnings per ADS of $1.96. Profitability has improved as BRUKINSA sales scaled and gross margin improved.